University Hospital Limerick
- Address
- lock Available on a paid plan
Breast Cancer Research
At University Hospital Limerick, a major focus is neoplasms research in breast cancer, especially early-stage, high-risk, and hormone receptor-positive disease. These studies are designed to improve outcomes by testing new treatment combinations, refining adjuvant care, and identifying which patients are most likely to benefit from chemotherapy or targeted therapy.
- Hormone receptor-positive, HER2-negative early breast cancer
- HER2-positive breast cancer with residual disease after surgery
- Triple-negative breast cancer and high-risk recurrence settings
- Personalized treatment decisions using risk and biomarker guidance
This work reflects an active effort to make breast cancer treatment more precise, effective, and tailored to individual risk.
Lung Cancer and Respiratory Research
The site also has strong activity in respiratory tract diseases and neoplasms, with multiple trials in non-small cell lung cancer. Research here explores new immunotherapy, targeted therapy, and combination approaches for advanced and early-stage disease, with the goal of improving survival and reducing recurrence after standard treatment.
- Advanced and metastatic non-small cell lung cancer
- KRAS G12C-mutant lung cancer
- Stage IV and post-surgery lung cancer
- Testing new therapies against established treatment options
These studies are helping advance treatment options for people with difficult-to-treat lung cancers.
Hematology and Blood Cancer Trials
Hemic and lymphatic diseases are a major research area at University Hospital Limerick, with studies in leukemia, lymphoma, and myeloma. The trials aim to improve disease control, deepen remission, and extend progression-free survival through newer targeted and immune-based therapies.
- Chronic lymphocytic leukemia and small lymphocytic lymphoma
- Mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma
- Acute myeloid leukemia and myelodysplastic syndromes
- Multiple myeloma, including newly diagnosed and relapsed disease
Overall, this research is focused on improving treatment effectiveness for a broad range of blood cancers.
Colorectal and Digestive Surgery Studies
Within its General and Colorectal Surgery department, the hospital is studying ways to reduce complications and improve recovery in colorectal cancer and elective bowel surgery. The research includes efforts to prevent surgical site infection and to support safer surgical care for patients undergoing major abdominal procedures.
- Colon cancer and rectal cancer
- Elective colorectal surgery
- Prevention of post-operative infection
- Improving surgical outcomes and recovery
This work combines cancer care with practical studies aimed at making surgery safer and more effective.
Prostate and Male Urogenital Disease Research
Research in male urogenital diseases at this site includes several studies in prostate cancer, especially advanced and metastatic disease. These trials are evaluating new hormonal and immune-based treatment strategies to delay progression and improve long-term disease control.
- Metastatic hormone-sensitive and hormone-naïve prostate cancer
- Advanced prostate cancer requiring systemic treatment
- Testing treatment strategies that balance effectiveness and quality of life
- Exploring improved outcomes for men with advanced disease
The research supports more individualized care for men facing advanced prostate cancer.
Ovarian, Peritoneal, and Other Solid Tumor Studies
The trial portfolio also includes neoplasms research across several other solid tumors, including ovarian cancer, stomach cancer, oesophageal cancer, and malignant peritoneal neoplasm. These studies are designed to test newer therapies, improve disease-free survival, and better define maintenance or post-treatment strategies.
- Advanced ovarian, fallopian tube, and primary peritoneal cancers
- Gastrointestinal cancers such as stomach and oesophageal cancer
- Post-treatment maintenance and recurrence prevention
- Evaluating whether new treatments improve survival outcomes
This broad solid-tumor research shows a strong commitment to improving care across multiple cancer types at University Hospital Limerick.
Infection, Clotting, and Supportive Care Research
Beyond cancer-focused studies, the site is also involved in bacterial infections and mycoses and cardiovascular diseases research linked to patient safety and supportive care. These trials look at preventing infection, reducing blood clot risk, and improving treatment tolerance in people living with serious illness.
- Surgical site infection prevention
- Venous thromboembolism in patients with cancer
- Supportive treatment for anemia and other treatment-related complications
- Improving safety alongside active disease treatment
These studies add an important supportive-care dimension to the broader clinical research program.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 87 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Limerick
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 87 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Docetaxel | 6 | Unknown | 2012-04-26 | 2026-04-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.